Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

Diffuse large B-cell lymphoma, the most common non-Hodgkin's lymphoma, is successfully treated in about two thirds of patients with rituximab-based immunochemotherapy. When current frontline immunochemotherapy fails, high-dose chemotherapy with autologous stem-cell transplantation can lead to…

from Cancer via ola Kala on Inoreader http://ift.tt/2ycc1ra
via IFTTT